February 6, 2020

Oz Adler
Chief Financial Officer
Therapix Biosciences Ltd.
4 Ariel Sharon Street
HaShahar Tower, 16th Floor
Givatayim 5320047, Israel

       Re: Therapix Biosciences Ltd.
           Registration Statement on Form F-1
           Filed January 31, 2020
           File No. 333-236175

Dear Mr. Adler:

       We have limited our review of your registration statement to those
issues we have
addressed in our comments.

       Please respond to this letter by amending your registration statement.
If you do not
believe our comments apply to your facts and circumstances or do not believe an
amendment is
appropriate, please tell us why in your response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Registration Statement on Form F-1

Description of the Offered Securities, page 24

1.     We note the arbitration provision in Section 22(c)(3) of your Articles
of Association filed
       as Exhibit 4.1 to your registration statement. Please revise your
prospectus to describe the
       arbitration provision and to clarify, if true, that the arbitration
provision is not mandatory
       and does not apply to claims brought under the United States federal
securities laws.
Incorporation of Certain Information by Reference, page 38

2.     We note that you incorporate information by reference into your
registration statement.
       However, to be eligible to incorporate by reference, you must have filed
your annual
       report required under Section 13(a) or Section 15(d) of the Exchange Act
for your most
       recently completed fiscal year. See General Instruction VI.C to Form
F-1. Please amend
 Oz Adler
Therapix Biosciences Ltd.
February 6, 2020
Page 2
         the registration statement to include all disclosure required by Form
F-1, or, in the
         alternative, file your Form 20-F for the fiscal year ended December
31, 2019.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Courtney Lindsay at 202-551-7237 or Irene Paik at
202-551-6553 with
any questions.



FirstName LastNameOz Adler                                      Sincerely,
Comapany NameTherapix Biosciences Ltd.
                                                                Division of
Corporation Finance
February 6, 2020 Page 2                                         Office of Life
Sciences
FirstName LastName